RGC
Price
$17.25
Change
+$0.15 (+0.88%)
Updated
Oct 6 closing price
Capitalization
8.53B
SUPN
Price
$48.16
Change
-$0.15 (-0.31%)
Updated
Oct 7, 12:22 PM (EDT)
Capitalization
2.71B
35 days until earnings call
Interact to see
Advertisement

RGC vs SUPN

Header iconRGC vs SUPN Comparison
Open Charts RGC vs SUPNBanner chart's image
Regencell Bioscience Holdings
Price$17.25
Change+$0.15 (+0.88%)
Volume$148.35K
Capitalization8.53B
Supernus Pharmaceuticals
Price$48.16
Change-$0.15 (-0.31%)
Volume$100
Capitalization2.71B
RGC vs SUPN Comparison Chart in %
RGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGC vs. SUPN commentary
Oct 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGC is a StrongBuy and SUPN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 07, 2025
Stock price -- (RGC: $17.25 vs. SUPN: $48.31)
Brand notoriety: RGC and SUPN are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: RGC: 60% vs. SUPN: 88%
Market capitalization -- RGC: $8.53B vs. SUPN: $2.71B
RGC [@Pharmaceuticals: Generic] is valued at $8.53B. SUPN’s [@Pharmaceuticals: Generic] market capitalization is $2.71B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.42B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGC’s FA Score shows that 0 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • RGC’s FA Score: 0 green, 5 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, SUPN is a better buy in the long-term than RGC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGC’s TA Score shows that 5 TA indicator(s) are bullish while SUPN’s TA Score has 3 bullish TA indicator(s).

  • RGC’s TA Score: 5 bullish, 3 bearish.
  • SUPN’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, RGC is a better buy in the short-term than SUPN.

Price Growth

RGC (@Pharmaceuticals: Generic) experienced а +5.25% price change this week, while SUPN (@Pharmaceuticals: Generic) price change was +1.49% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.20%. For the same industry, the average monthly price growth was +6.19%, and the average quarterly price growth was +61.58%.

Reported Earning Dates

SUPN is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.20% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGC($8.53B) has a higher market cap than SUPN($2.71B). RGC YTD gains are higher at: 13169.125 vs. SUPN (33.601). SUPN has higher annual earnings (EBITDA): 174M vs. RGC (-3.99M). SUPN has more cash in the bank: 523M vs. RGC (2.96M). RGC has less debt than SUPN: RGC (85.7K) vs SUPN (31.8M). SUPN has higher revenues than RGC: SUPN (665M) vs RGC (0).
RGCSUPNRGC / SUPN
Capitalization8.53B2.71B315%
EBITDA-3.99M174M-2%
Gain YTD13169.12533.60139,193%
P/E RatioN/A42.01-
Revenue0665M-
Total Cash2.96M523M1%
Total Debt85.7K31.8M0%
FUNDAMENTALS RATINGS
RGC vs SUPN: Fundamental Ratings
RGC
SUPN
OUTLOOK RATING
1..100
2516
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
10034
SMR RATING
1..100
10081
PRICE GROWTH RATING
1..100
3440
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SUPN's Valuation (77) in the Pharmaceuticals Other industry is in the same range as RGC (95) in the Movies Or Entertainment industry. This means that SUPN’s stock grew similarly to RGC’s over the last 12 months.

SUPN's Profit vs Risk Rating (34) in the Pharmaceuticals Other industry is significantly better than the same rating for RGC (100) in the Movies Or Entertainment industry. This means that SUPN’s stock grew significantly faster than RGC’s over the last 12 months.

SUPN's SMR Rating (81) in the Pharmaceuticals Other industry is in the same range as RGC (100) in the Movies Or Entertainment industry. This means that SUPN’s stock grew similarly to RGC’s over the last 12 months.

RGC's Price Growth Rating (34) in the Movies Or Entertainment industry is in the same range as SUPN (40) in the Pharmaceuticals Other industry. This means that RGC’s stock grew similarly to SUPN’s over the last 12 months.

RGC's P/E Growth Rating (100) in the Movies Or Entertainment industry is in the same range as SUPN (100) in the Pharmaceuticals Other industry. This means that RGC’s stock grew similarly to SUPN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGCSUPN
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
63%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
68%
Momentum
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
N/A
Bearish Trend 6 days ago
58%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
71%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 7 days ago
75%
Declines
ODDS (%)
Bearish Trend 14 days ago
89%
Bearish Trend 23 days ago
63%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
RGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LGRRX30.33N/A
N/A
Loomis Sayles Growth A
OEQAX10.41N/A
N/A
Oaktree Emerging Markets Equity A
RYTFX7.97N/A
N/A
Royce Small-Cap Total Return Svc
URITX33.56N/A
N/A
Victory International R6
JGQYX18.78N/A
N/A
Jensen Global Quality Growth Y

RGC and

Correlation & Price change

A.I.dvisor tells us that RGC and QNTM have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RGC and QNTM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGC
1D Price
Change %
RGC100%
+0.88%
QNTM - RGC
21%
Poorly correlated
-3.12%
SBFM - RGC
20%
Poorly correlated
N/A
CPHI - RGC
13%
Poorly correlated
-0.85%
ANIP - RGC
11%
Poorly correlated
+2.70%
SUPN - RGC
7%
Poorly correlated
-0.08%
More